495. Upscaling of Retroviral Vector Production under GMP Guidelines to Generate High Titer Preparations for Clinical Use
Molecular Therapy(2005)
Abstract
High titer retroviral vector supernatant, produced in compliance with GMP, has always been a prerequisite for gene therapy purposes in clinical trials. But most vector production procedures have their limitations: the vector often leads only to low titer supernatant, only a few harvest cycles can be done and harvest volumes are often small.
MoreTranslated text
Key words
mt, INSERT KEY WORDS HERE, pharmacology
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined